N/A N=22 Diagnosing Intensive Care Unit (ICU) Acquired Weakness
ICU Acquired Weakness
Primary: Peak Acceleration Measured in Extensor Carpi Radialis Longus — 0.476; 1.639; 0.541; 1.608 units of Gravity
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=9 Neurosciences-Intensive Care Unit Electrical Stimulation
Intensive Care (ICU) Myopathy
Primary: Duration of Intubation — 10.22 days
N/A N=120 Treatment of Critical Illness Polyneuromyopathy
Acute Respiratory Failure
Primary: The Primary Outcome Variable for This Study Will be the Short Form of the Continuous Scale Physical Functional Performance Test (CS-PFP) Called the PFP-10 — 19.0; 20.9…
N/A N=34 Use of Neuromuscular Electrostimulation (NMES) for Treatment or Prevention of ICU-Associated Weakness
Intensive Care Unit · Muscle Weakness
Primary: Lower Extremity Strength, at Hospital Discharge, of 3 Bilateral Muscle Groups (Pretibial, Triceps Surae, and Quadriceps) Measured Via MMT Using a Composite Medical…
N/A N=73 Effect of EPA and HMB on Strength in ICU Patients
Muscle Weakness
Primary: Change of Skeletal Muscle Strength for One of the Drugs Compared to Placebo — 1.3; 0.1; 1.5; 0.7 cm H2O
Phase 1 N=19 Electrical Stimulation for Critically Ill Covid-19 Patients
Covid19 · Muscle Atrophy · Muscle Weakness
Primary: Change in Gastrocnemius Muscle Endurance (Muscle Sustained Contraction) in Response to Electrical Stimulation — 352; 323 milliVolts
N/A N=232 Vanderbilt ICU Recovery Program Pilot Trial
Intensive Care Unit Syndrome · Intensive Care Neurological Disorder · Intensive Care (ICU) Myopathy
Primary: Number of Components of the ICU Recovery Program Received — 2; 1 interventions
N/A N=1,609 24 Hour Intensivist Coverage in the Medical Intensive Care Unit
Critically Ill
Primary: MICU Length of Stay — 52.8; 52.6 hours
Phase 2 N=19 Electrical Stimulation for Critically Ill Post-Covid-19 Patients
COVID-19 · Muscle Atrophy · Muscle Weakness
Primary: Gastrocnemius Muscle Endurance (Muscle Sustained Contraction) in Response to Electrical Stimulation — 363.04; 359.55 miliVolts
N/A N=20 Preventing the Loss of Muscle and Function in Hospitalized Older Adults
Muscular Atrophy
Primary: The Percent Change in Bilateral Thigh Lean Mass Density (Grams) as Measured by DEXA Scan Will be Compared Between Baseline and After 5-days of Bed Rest — -3.845; -0.249…
N/A N=7 A Randomized, Controlled Trial of Inspiratory Muscle Training (IMT)in the ICU and CCU
Critically Ill · Respiratory Failure
Primary: Safety and Feasibility of Inspiratory Muscle Training — 3; 3 Participants
N/A N=100 High Protein, Core Muscle Rehab, Muscular Electrostimulation in Prolonged Mechanical Ventilation
Prolonged Mechanical Ventilation · Protein Deficiency
Primary: Weaning Rate — 3; 20; 22; 26 Participants
N/A N=252 Impact on Mental, Physical, And Cognitive Functioning of a Critical Care sTay During the COVID-19 Pandemic
Covid19 · Critical Care · Postintensive Care Syndrome
Primary: World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) — 5; 13.5 units on a scale
Phase 3 N=24 Arimoclomol in Sporadic Inclusion Body Myositis
Inclusion Body Myositis
Primary: Count of Adverse Events Reported — 109; 52 adverse events reported
Phase 2 N=63 Antioxidant Therapy in RYR1-Related Congenital Myopathy
Neuromuscular Disease
Primary: Urine 15-F2t Isoprostane Concentration — 2.7; 2.6 ng/mg Cr — p=0.88
N/A N=15,724 Intensive Monitoring of Renal Function
Intensive Monitoring of Renal Function · Acute Kidney Injury
Primary: Detection of Acute Kidney Injury (AKI) — 1.22; 1.22; 1.11; 1.11 Odds Ratio
N/A N=677 Unexpected Cardiac Arrest in Intensive Care Unit
Heart Arrest
Primary: Number of Patients With Unexpected Cardiac Arrest — 677; 30,722 Participants
Phase 4 N=420 Succinylcholine Versus Rocuronium for Emergency Intubation in Intensive Care
Intubation
Primary: Number of Participants Exhibiting Desaturation >5% — 73; 66 participants
Phase 2 N=18 Early Insulin and Development of ARDS
Respiratory Distress Syndrome, Adult · Sepsis · Hyperglycemia
Primary: Plasma Levels of Free Fatty Acids, Tumor Necrosis Factor-α, Interleukin-6, and Von Willebrand Factor Antigen
N/A N=33 Novel Intervention to Influence Muscle Plasticity in Veterans
Spinal Cord Injuries
Primary: HF Muscle Force — 23.9; 30.9 Newtons (N)
N/A N=153 Improving the Recovery and Outcome Every Day After the ICU
Delirium · Alzheimer Disease
Primary: Cognitive Status Outcome at 6 Months — 0.24; 0.36; 0.21; 0.35 Z-score — p=0.747
Phase 3 N=274 Hypovitaminosis D in Neurocritical Patients
Craniocerebral Trauma · Intracranial Aneurysm · Brain Neoplasms
Primary: Intent-to-treat Hospital Length-of-stay — 10.9; 9.1 days — p=0.2
N/A N=5,094 Second Survey of Intensive Care in India
Critical Illness
Primary: ICU Mortality — 1092 Participants
N/A N=37 Forearm Immobilization, Metabolic Health, and Muscle Loss
Healthy
Primary: Percent Change in Forearm Glucose Uptake — -73; 127; -95 Percent change in clamp FGU with immob
N/A N=70 Effect of Succinylcholine on Patients Using Statins
Pain
Primary: Plasma Myoglobin Concentration — 46; 39; 71; 49 ug/l — p=0.018
Phase 2 N=31 Vitamin D in Ventilated ICU Patients
Respiratory Failure
Primary: Number of Participants With Plasma 25(OH)D Concentration >30ng/mL at Baseline — 2; 2; 1 participants
N/A N=4,652 The Thai Surgical Intensive Care Study (Thai-SICU Study)
Complications of Surgical and Medical Care: General Terms · Adverse Reaction to Drug · Sequelae of External Causes of Morbidity and Mortality
Primary: Overall Mortality — 642 participants
N/A N=53 Electrical Stimulation in Patients With Prolonged Mechanical Ventilation
Respiratory Failure
Primary: Level of Activity of Daily Life — 25.2; 32.0 units on a scale — p=0.652
Phase 3 N=1,008 Reevaluation Of Systemic Early Neuromuscular Blockade
Acute Respiratory Distress Syndrome
Primary: Hospital Mortality to Day 90 — 288; 289; 213; 216 Participants — p=0.93
Phase 2 N=83 Neuromuscular Blockade for Post-Cardiac Arrest Care
Cardiac Arrest
Primary: Change in Lactate Over 24 Hours — -2.2; -2.3 mmol/L